Clinical psychiatric evaluations of patients have changed dramatically in recent decades. Both initial assessments and follow-up visits have become brief and superficial, focused on searching for categorical diagnostic criteria from checklists, with limited inquiry into patient-reported symptomatic status and tolerability of treatments. The virtually exclusive therapeutic task has become selecting a plausible psychotropic, usually based on expert consensus guidelines. These guidelines and practice patterns rest mainly on published monotherapy trials that may or may not be applicable to particular patients but are having a profound impact, not only on modern psychiatric practice but also on psychiatric education, research, and theory.
CraddockNMynors-WallisL.Psychiatric diagnosis: Impersonal, imperfect and important. Br J Psychiatry. 2014;204:93–95.
2.
GardnerDM. Competent psychopharmacology. Can J Psychiatry. 2014;59(8):406–411.
3.
MadduxJEWinsteadBA. Psychopathology: Foundations for a contemporary understanding. Mahwah (NJ): Lawrence Erlbaum; 2005.
4.
CloningerCR. Implications of comorbidity for the classification of mental disorders: The need for a psychobiology of coherence. In: MajMGoebelWLopez-IborJJ, editors. Psychiatric diagnosis and classification. Chichester (GB): Wiley; 2002. p 79–106.
5.
KapczinskiFVideira DiasVKauer-Sant'AnnaM, Potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Progr Neuropsychopharmacol Biol Psychiatry. 2009;33:1366–1371.
6.
FavaGAGuidiJSempriniF, Clinical assessment of allostatic load and clinimetric criteria. Psychother Psychosom. 2010;79(5):280–284.
7.
LichtenbergPBelmakerRH. Subtyping major depressive disorder. Psychother Psychosom. 2010;79(3):131–135.
8.
BaldessariniRJ. Impact of psychopharmacology on contemporary psychiatry [guest editorial]. Can J Psychiatry. 2014;59(8):401–405.
9.
ÖsbyUBrandtLCorreiaN, Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–850.
10.
SimonRIHalesRE, editors. Textbook of suicide assessment and management. 2nd ed.Washington (DC): American Psychiatric Publishing; 2012.
11.
TondoLBaldessariniRJ. Clinical management of suicidal risk. In: YildizANemeroffCRuizP, editors. Bipolar disorder. New York (NY): Oxford University Press; forthcoming 2014 Oct.
12.
RayWAChungCPMurrayKT, Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235.
13.
CohenDBogersJPvan DijkD, Beyond white blood cell monitoring: Screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307–1312.
14.
BaldessariniRJ. Chemotherapy in psychiatry: The pharmacologic basis of treatments for major mental illness. 3rd ed.New York (NY): Springer Press; 2013.
15.
BaldessariniRJ. American biological psychiatry and psychopharmacology 1944–1994. Chapter 16. In: MenningerRWNemiahJC, editors. American psychiatry after World War II (1944–1994).Washington (DC): American Psychiatric Press; 2000. p 371–412.
16.
BondyB.Genetics in psychiatry: Are the promises met?World J Biol Psychiatry. 2011;12(2):81–88.
17.
FarahMJGillihanSJ. The puzzle of neuroimaging and psychiatric diagnosis: Technology and nosology in an evolving discipline. AJOB Neurosci. 2012;3(4):1–11.
18.
LindenDE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73(1):8–22.
19.
LehnerTSenthilGAddingtonAM. Convergence of advances in genomics, team science, and repositories as drivers of progress in psychiatric genomics. Biol Psychiatry. 2014 Jan 15. pii: S0006–3223(14)00014–6. doi: 10.1016/j.biopsych.2014.01.003. [Epub ahead of print].
20.
DekelRDrossmanDASperberAD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329–339.
21.
MercierAAuger-AubinILebeauJP, Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: Analysis of guidelines and systematic reviews. BMC Fam Pract. 2013;4(5);14:55–65.
22.
YathamLNKennedySHParikhSV, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2013;15:1–44.
23.
GardnerDMBaldessariniRJWaraichP.Modern antipsychotic agents: A critical overview. CMAJ. 2005;172:1703–1711.
24.
LeuchtSCorvesCArbterD, Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373(9657):31–41.
25.
HasanAFalkaiPWobrockT, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378.
26.
VietaEPappadopulosEMandelFS, Impact of geographical and cultural factors on clinical trials in acute mania: Lessons from a ziprasidone and haloperidol placebo-controlled study. Int J Neuropsychopharmacol. 2011;14(8):1017–1027.
27.
VázquezGHBaldessariniRJYildizA, Multi-site international collaborative trials in mania. Int J Neuropsychopharmacol. 2011;14(8):1013–1016.
28.
TurnerEHMatthewsAMLinardatosE, Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–260.
29.
SongFParekhSHooperL, Dissemination and publication of research findings: Updated review of related biases. Health Technol Assess. 2010;14(8):1–193.
30.
TurnerEH. Publication bias, with a focus on psychiatry: Causes and solutions. CNS Drugs. 2013;27(6):457–468.
31.
VázquezGHBaldessariniRJTondoL.Co-morbidity: Bipolar and anxiety disorders: Clinical and therapeutic overview. Depress Anxiety. 2014;31:196–206.
32.
ThaseME. Antidepressant combinations: Widely used, but far from empirically validated. Can J Psychiatry. 2011;56(6):317–323.
33.
FarahaniACorrellCU. Are antipsychotics or antidepressants needed for psychotic depression? Systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486–496.
34.
JureidiniJTonkinAJureidiniE.Combination pharmacotherapy for psychiatric disorders in children and adolescents: Prevalence, efficacy, risks and research needs. Paediatr Drugs. 2013;15(5):377–391.
